This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

It's Not Too Late to Profit on TearLab

As brittle as my confidence may be in buying stocks as such high levels, I don't see any alternatives on the market to compete with TearLab's system. And even if a product were to emerge today, it would be difficult to unseat the industry gains that TearLab has already won with doctors.

The fact that the company was able to secure almost 400 system orders in the first quarter, growing close to 70% year over year, speaks to the trust that TearLab has established. What this also means is that management now has a problem that every company "cries" for -- fulfillment/backlog challenges, or the ability to service overwhelming demand.

Along similar lines, given the company's ability to maintain/grow margins, while growing market share, I don't see what will stunt TearLab's growth or the stock's momentum. If there are any risks, it's with capital expenditure, which grew 63% in the recent quarter.

While it's not uncommon for small biotech companies to carry high costs, the magnitude in the year-over-year comparison was pretty significant, including 180% jump in sales and marketing expense. This is one of those cases where an investor has to shrug his/her shoulders and take the good with the bad and realize that you can't enjoy 486% revenue growth without spending for it.

I don't believe this changes the story significantly. But at some point, the cash is going to run out. It's worth asking what happens when TEAR is no longer able to spend to grow. The good news is that the TearLab's system serves large population of patients that benefit greatly from the technology.

Plus, the fact that doctors have been able to profit from the system means that TearLab also has plenty of support. Given this scenario, I believe that even with minimal spending, TearLab can still be effective. Besides, the order backlog should provide plenty of revenue to support near-terms cash-flow headwinds - should they arise.

In the meantime, given management's incredible level of execution, I can still see plenty of value in stock despite its already strong year-to-date gains of close to 200%. It wouldn't surprise me to see shares approach the $15 to $20 level some time during the second half of the year.

Lastly, Cramer also said, every once in a while we have to "settle with buying high to selling higher." If it helps, he said this while referencing TearLabs. This time I'm listening.

At the time of publication, the author held no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.
Richard Saintvilus is a private investor with an information technology and engineering background and the founder and producer of the investor Web site Saint's Sense. He has been investing and trading for over 15 years. He employs conservative strategies in assessing equities and appraising value while minimizing downside risk. His decisions are based in part on management, growth prospects, return on equity and price-to-earnings as well as macroeconomic factors. He is an investor who seeks opportunities whether on the long or short side and believes in changing positions as information changes.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TEAR $1.58 3.27%
AAPL $117.81 -0.19%
FB $105.45 0.04%
GOOG $750.26 0.28%
TSLA $231.61 0.86%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs